Free cash flow CAGR uses the stored cash-flow statement history.
Over the past 12 months, Free Cash Flow CAGR is N/A.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how the company's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
Caris Life Sciences, Inc. (CAI)
Free Cash Flow growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Reported quarterly free cash flow; no daily interpolation. Q2 FY2026 (2026-06-30): $28.94M.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures Quote observation: 2026-10-06T14:31:01.210Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Four-quarter free cash flow / FMP quote market capitalization × 100 Quote observation: 2026-10-06T14:31:01.210Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| Year | Start FCF | End FCF | Change | % Change |
|---|---|---|---|---|
| 2025 | −$253.64M | $66.89M | +$320.54M | N/A |
| 2024 | −$298.42M | −$253.64M | +$44.78M | N/A |
| 2023 | −$327.96M | −$298.42M | +$29.54M | N/A |
| 2022 | $57.57M | −$327.96M | −$385.53M | -669.71% |
| 2020 | −$65.14M | $57.57M | +$122.71M | N/A |
| 2019 | −$633.07M | −$65.14M | +$567.93M | N/A |
| 2018 | −$346.98M | −$633.07M | −$286.09M | N/A |
| 2017 | −$121.99M | −$346.98M | −$224.99M | N/A |
| 2016 | −$242.04M | −$121.99M | +$120.05M | N/A |
| 2015 | −$167.62M | −$242.04M | −$74.42M | N/A |
| 2014 | −$188.02M | −$167.62M | +$20.39M | N/A |
| 2013 | −$417.77M | −$188.02M | +$229.75M | N/A |
| 2012 | −$419.82M | −$417.77M | +$2.05M | N/A |
| 2011 | −$164.41M | −$419.82M | −$255.42M | N/A |
| 2010 | −$555.00K | −$164.41M | −$163.85M | N/A |
| 2009 | −$176.86M | −$555.00K | +$176.31M | N/A |
| 2008 | −$219.93M | −$176.86M | +$43.07M | N/A |
| 2007 | −$37.48M | −$219.93M | −$182.46M | N/A |
| 2006 | $29.06M | −$37.48M | −$66.54M | -228.95% |
| 2005 | −$125.73M | $29.06M | +$154.80M | N/A |
| 2004 | −$60.70M | −$125.73M | −$65.03M | N/A |
| Period | Period End | Value | QoQ Growth | YoY Growth |
|---|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | $28.94M | +28.4% | N/A |
| Q1 FY2026 | 2026-03-31 | $22.53M | -43.2% | N/A |
| Q4 FY2025 | 2025-12-31 | $39.69M | -28.3% | N/A |
| Q3 FY2025 | 2025-09-30 | $55.33M | N/A | N/A |
| Q2 FY2025 | 2025-06-30 | $5.90M | N/A | N/A |
| Q1 FY2025 | 2025-03-31 | -$34.03M | N/A |
| N/A |
| Q4 FY2024 | 2024-12-31 | -$41.21M | +42.2% | N/A |
| Q3 FY2024 | 2024-09-30 | -$71.25M | N/A | N/A |
| Q2 FY2024 | 2024-06-30 | -$65.51M | +13.4% | N/A |
| Q1 FY2024 | 2024-03-31 | -$75.66M | N/A | N/A |
| Q3 FY2021 | 2021-09-30 | -$447.56M | -2280.1% | N/A |
| Q2 FY2021 | 2021-06-30 | -$18.80M | +80.4% | N/A |
| Q1 FY2021 | 2021-03-31 | -$95.86M | -4.9% | N/A |
| Q4 FY2020 | 2020-12-31 | -$91.42M | N/A | N/A |
| Q3 FY2020 | 2020-09-30 | $56.28M | -6.8% | N/A |
| Q2 FY2020 | 2020-06-30 | $60.38M | +86.9% | +72.6% |
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
